Syntagon AB

Activities: Regulatory Research & Development

Trending Articles

  1. IMPACT CKD model reveals the escalating toll of chronic kidney disease The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  3. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  4. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
  5. ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Media

Ardena acquires Syntagon

Contract development and manufacturing organisation acquires a specialist contract manufacturer of novel active pharmaceutical ingredients and excipients, strengthening its API offering

Syntagon successfully renews GMP accreditation

<p>Specialist contract research organisation, Syntagon, has successfully renewed its Good Manufacturing Practices (GMP) certification for themanufacture of clinical active pharmaceutical ingredients (APIs) following an audit by the Swedish Medical Products Agency.</p>
Media

Syntagon to open Shanghai operation

<p>Scandinavian drug development company Syntagon is to expand its global presence by opening new premises in Shanghai. The expansion is set to bolster Syntagon's raw material sourcing capabilities - often a considerable cost element in clinical API production.</p>
Subscribe now